To print: Select File and then Print from your browser's menu

Title: Atomoxetine Improves Multiple Symptoms in ADHD With Comorbid Anxiety: Presented at AACAP

"Atomoxetine Improves Multiple Symptoms in ADHD With Comorbid Anxiety: Presented at AACAP"

By Paula Moyer SAN DIEGO, CA -- November 2, 2006 -- Patients with attention deficit/hyperactivity disorder (ADHD) and comorbid anxiety get some relief from both conditions when they are treated with atomoxetine (Strattera), according to investigators speaking here at the 53[^rd annual meeting of the American Academy of Child and Adolescent Psychiatry (AACAP).

"Atomoxetine was efficacious in treating ADHD symptoms in children and adolescents with these 2 conditions," said principal investigator Daniel Geller, MBBS, researcher, pediatric psychopharmacology research program, Massachusetts General Hospital, Cambridge, Massachusetts. "It did not exacerbate comorbid anxiety."

Dr. Geller and his co-investigators conducted the study because of their concern that 25% to 50% of patients with ADHD have comorbid anxiety disorders, Dr. Geller said in a presentation on October 26^th. Therefore, they conducted a study involving 176 patients with ADHD who also had comorbid anxiety.

Patients were randomized to receive either atomoxetine or placebo for 12 weeks; for patients on active treatment, the targeted dose was 1.2 mg/kg/day, with increases up to 1.8 mg/kg/day in patients who did not respond to the targeted treatment.

The treatment measures were the Multidimensional Anxiety Scale for Children (MASC), the Life Participation Scale for ADHD-Revised (LPS-ADHD-R), the Child Health Questionnaire-Parent Completed Full Length (CHQ-PF50), and the Clinical Global Impression-Severity scale (CGI-S).

Among the original patients, 132 completed the study, 66 in each group. Treated patients had a significantly greater improvement on the MASC, a decrease of 4.6 points, compared with those on placebo, who had a decrease of 2.1 points (P = .009). Similarly, on the LPS-ADHD-R, treated patients had an increase of 9.5 points and those on placebo has an increase of 3.1 points (P = .002). Treated patients also had significantly greater improvements on the CHQ-PF50 Psychosocial subscale, an increase of 6.9 points compared with an increase of 3.3 points in the placebo group (P = .019). And on the CGI-S, treated patients had a decrease of 0.9 points and those on placebo had a decrease of 0.4 points (P = .002).

Decreased appetite was the only adverse effect experienced by significantly more by treated patients than those on placebo, which occurred in 14.3% of treated patients and in 3.8% of those on placebo (P = .025).

"The results provide evidence of the effect of atomoxetine in treating anxiety symptoms in this population," the investigators reported. "Patient-reported improvements in anxiety symptoms were consistent with investigator-reported improvements in children with ADHD and comorbid anxiety."

The study was funded by Eli Lilly and Company, which manufactures Strattera.

[Presentation title: Atomoxetine Treatment for Pediatric Patients With ADHD and Comorbid Anxiety. Abstract C9]

Copyright © 2009 P\S\L Consulting Group Inc. All rights reserved. Republication or redistribution of P\S\L content is expressly prohibited without the prior written consent of P\S\L. P\S\L shall not be liable for any errors, omissions or delays in this content or any other content on its sites, newsletters or other publications, nor for any decisions or actions taken in reliance on such content.